UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

Core Insights - UNITY Biotechnology, Inc. has appointed Alicia Tozier as chief strategy officer to develop and implement corporate and product strategies [1][6] - Ms. Tozier has 20 years of experience in the pharma and medical device industry, with a strong background in ophthalmology and a proven track record of successful product launches [2][6] - The company is focused on developing therapeutics to slow, halt, or reverse diseases of aging, particularly targeting age-related ophthalmologic and neurologic diseases [7] Company Overview - UNITY is a biotechnology company that aims to create medicines that selectively eliminate or modulate senescent cells [7] - The current lead program, UBX1325, is positioned to transform the treatment landscape for diabetic macular edema (DME) [6][7] - UNITY's strategic direction is expected to benefit from Ms. Tozier's expertise in commercial strategy and product planning [6] Leadership and Strategy - Alicia Tozier's previous roles include senior vice president at Outlook Therapeutics and head of ophthalmology at Genentech Pharmaceuticals, where she led significant market access and product launches [2][6] - The CEO of UNITY, Anirvan Ghosh, expressed confidence in Ms. Tozier's ability to drive the company's strategic vision and operational excellence [6] - Ms. Tozier is optimistic about UNITY's potential as it transitions into a late-stage clinical development organization [7]